EGFR and head and neck squamous cell carcinoma: A recent clinical trial (NCT02415881) in head and neck squamous cell carcinoma used an anti-epidermal growth factor receptor contrast agent (panitumumab-IRDye800CW) and showed that the signal to background ratio was significantly higher in high-grade dysplasia as compared to low grade dysplasia/normal (p < 0.05) [33].